metaboliqWhat these medicines are
GLP-1 is a hormone your gut releases after a meal. It tells the brain you have eaten and helps the pancreas release insulin when blood sugar rises. The medicines in these guides copy that signal and make it last for days instead of minutes.
Semaglutide acts on the GLP-1 receptor alone. Tirzepatide acts on GLP-1 and a second gut hormone, GIP. Each is sold in India under more than one brand, as a once-weekly pen and, for semaglutide, also as a daily tablet. Generic semaglutide has been sold in India since March 2026.
Who decides
Every one of these is a Schedule H medicine: a pharmacy may sell it only against a registered doctor's prescription. Whether one suits you is a clinical decision, made by a doctor who has your history, your examination and your blood results in front of them.
No programme price covers any medicine. Medicine, if your doctor prescribes it, is billed separately each month. It is dispensed only against a registered doctor's prescription, by a licensed pharmacy. A doctor on our panel reads your blood and your history with you, and what comes next is decided between the two of you.
Why the blood comes first
The labels of these medicines list situations in which they must not be used, and others that need closer watching. Your thyroid, liver, kidney, sugar control and lipids are part of how a doctor checks those. A questionnaire cannot see them; a blood panel can.
How these guides are written
Each guide says what a medicine is approved for in India, how it works, its common and serious side effects, and what its costs on record are. Every statement links to its source: the trial papers, the regulator's documents and the product labels.
Each guide is reviewed by a registered doctor on our published panel, whose name, qualification and registration number appear on it, with the date of the review. A guide is published only after that review.